Day: May 20, 2024

Nokia CorporationStock Exchange Release20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 370,393 3.56CEUX – –BATE – –AQEU – –TQEX – –Total 370,393 3.56* Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation...

BEIJING, China, May 20, 2024 (GLOBE NEWSWIRE) — ZW Data Action Technologies Inc. (NASDAQ: CNET) (“ZW Data Action” or the “Company”), an integrated online advertising, precision marketing, data analytics and other value-added services provider serving enterprise clients, today announced that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2024 notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Form 10-Q”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic...

The new Pennsylvania location brings the number of facilities the carrier operates in the state to seven JOHNS CREEK, Ga., May 20, 2024 (GLOBE NEWSWIRE) — Saia Inc. (NASDAQ: SAIA) announced that Saia LTL Freight’s newest Pennsylvania terminal, in Reading, commenced operations today. The facility will provide customers with more direct shipping points across the Northeast and beyond. “We are excited to be a part of the Reading community, which is a new market for us,” said Vice President of Operations, East Jared Mull. “The local economy is growing, so we are happy to help facilitate added growth by providing shipping services as well as jobs. This location is also important as it will offer increased flexibility and better overall service for Saia customers.” Thus far this year, Saia has opened new facilities in Montana, New Jersey,...

Discover the appeal of Japanese companies listed in the U.S.Japan IR Event at NadaqJapan IR Event at NadaqJapan IR Event at NadaqJapan IR Event at NadaqNEW YORK, May 20, 2024 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM”, the “Company”), today announced it will participate in a “NASDAQ JAPAN IR EVENT” to be held at Nasdaq MarketSite in Times Square on June 20, 2024. Five companies are currently expected to join this event (including one private company), and we will share information about the attractive nature of the Japanese market with a global audience. PurposeIn December 2020, the Company became the first Japanese company in 21 years to list on Nasdaq. Today, the number of Japanese companies listed on Nasdaq has increased...

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model KRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) —  Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD. New data for KRRO-110 shows approximately 60% editing...

World’s most powerful and secure ultra-mobile AI PCs drive next generation of AI computing with record-breaking 26 hours of battery life 1, 2, 3 News Highlights:World’s most powerful ultra-mobile next-gen AI PCs1 reclaim time for meaningful work and creation Unleash your full potential from anywhere with the world’s longest battery life in an ultra-mobile next-gen AI PC3 Sleek new HP next-gen AI PCs deliver lightning-fast responsiveness with a dedicated NPU4 capable of 45 trillion operations per second (TOPS) Discover new AI superpowers to create, work, learn, and focus like a pro with HP next-gen AI PCs HP introduces the world’s most secure next-gen AI PC2 to protect against AI-generated threatsREDMOND, Wash., May 20, 2024 (GLOBE NEWSWIRE) — Today HP Inc. unveiled a new class of next-generation AI PCs at Microsoft’s AI Vision...

  Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMNOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPDParis and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of...

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking data from the NOTUS Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e.,...